Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6

Published:2022-06-21 Issue:7 Volume:134 Page:654-658
ISSN:0032-5481
Container-title:Postgraduate Medicine
language:en
Short-container-title:Postgraduate Medicine

Author:

Hammerman Ariel¹^ORCID,Moore Candace Makeda²^ORCID,Aboalhasan Enis³^ORCID,Azuri Joseph⁴⁵^ORCID,Arbel Ronen¹³^ORCID

Affiliation:

1. Community Medical Services, Clalit Health Services Headquarters, Tel Aviv, Israel

2. Research Software department, Netherlands eScience Center, Amsterdam, The Netherlands

3. Maximizing Health Outcomes Research Lab, Sapir College, Sderot, Israel

4. Maccabi Healthcare Services, Diabetes Clinic, Tel Aviv, Israel

5. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00325481.2022.2090794

Reference23 articles.

1. Diabetes Mellitus and Cardiovascular Disease

2. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I

3. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis

4. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP